Latest:
Dr. Santos on the Current Treatment Landscape in Squamous Cell Carcinoma of the Lung
Edgardo S. Santos, MD, FACP, discusses the current treatment landscape for patients with squamous cell carcinoma of the lung.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Edibaldo Silva, MD, PhD
Latest:
Back to the Future: Why Are More Women Having Bilateral Mastectomy for Unilateral Breast Cancer?
Since 2003, the rate of women choosing breast-conserving surgery for the
management of early-stage breast cancer has declined, with an accompanying
recidivism to mastectomy. Edibaldo Silva, MD, PhD, examines the reasons for
the treatment regression.
Edith Mitchell, MD, FACP
Latest:
Dr. Mitchell on ECOG-ACRIN’s Efforts in Addressing Health Disparities in Cancer Care
Edith P. Mitchell, MD, MACP, FCPP, FRCS, shared the inspiration behind the ECOG-ACRIN Health Equity Committee, and discusses ECOG-ACRIN’s efforts in addressing health disparities in cancer care.
Edouard J. Trabulsi, MD
Latest:
Dr. Trabulsi on Clinical Trial Combination Approaches in Prostate Cancer
Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, discusses clinical trials that are investigating combination approaches for patients with prostate cancer.
Edouard J. Trabulsi, MD, FACS
Latest:
Dr. Trabulsi Discusses Postoperative Radiation in Prostate Cancer
Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, discusses postoperative radiation in patients with prostate cancer.
Eduardo Fernandez, MD
Latest:
Hypofractionated and Stereotactic Body Radiotherapy in Prostate Cancer
Despite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.
Eduardo Fernandez MD, PhD
Latest:
Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter Validation
Rapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.
Eduardo Fernandez, MD, PhD, FACRO
Latest:
Dr. Fernandez Discusses Immunotherapy Plus Radiation Therapy for Prostate Cancer
Eduardo Fernandez, MD, PhD, FACRO, Senior Vice President, Medical Affairs / Medical Director for Latin America, Radiation Oncologist, 21st Century Oncology, discusses the potential for immunotherapy and radiation therapy to be used together to treat prostate cancer.